Regeneron Pharmaceuticals Inc (REGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $98.84B
Last updated: Nov 17, 2026 at 11:06 AM ET
Regeneron Pharmaceuticals Inc (REGN) Earnings: Report Dates and Results
Regeneron Pharmaceuticals (REGN) is expected to report earnings on Jan 28, 2027. In the quarter ended Sep 30, 2026, Regeneron Pharmaceuticals reported EPS of $18.43, above the $13.76 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
REGN has an expected report date of Jan 28, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 129.6% above the $11.44 reported for the quarter ended Dec 31, 2025.
REGN Earnings Call
The latest REGN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, REGN beat 35 and missed 5. Revenue for the quarter ended Sep 30, 2026 was $5.12B, up 36.5% from $3.75B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $18.43 | $13.76 | N/A | +33.94% | Beat | +55.8% | 23 | 3 up, 2 down | Oct 30, 2026 | $5.12B |
| Jun 30, 2026 | $12.53 | $8.00 | $7.64 - $12.33 | +56.63% | Beat | -2.8% | 22 | 0 up, 1 down | Jul 30, 2026 | $4.29B |
| Mar 31, 2026 | $9.47 | $8.90 | $5.40 - $12.75 | +6.40% | Beat | +15.2% | 23 | 7 up, 8 down | Apr 29, 2026 | $3.61B |
| Dec 31, 2025 | $11.44 | $10.75 | $8.38 - $13.78 | +6.42% | Beat | -5.2% | 19 | 5 up, 5 down | Jan 30, 2026 | $3.88B |
| Sep 30, 2025 | $11.83 | $9.64 | $7.61 - $10.57 | +22.72% | Beat | -5.1% | 23 | 5 up, 9 down | Oct 28, 2025 | $3.75B |
| Jun 30, 2025 | $12.89 | $8.44 | $4.25 - $9.45 | +52.73% | Beat | +11.5% | 21 | 5 up, 9 down | Aug 1, 2025 | $3.68B |
| Mar 31, 2025 | $8.22 | $8.48 | $6.11 - $10.73 | -3.07% | Miss | -13.9% | 20 | 2 up, 12 down | Apr 29, 2025 | $3.03B |
| Dec 31, 2024 | $12.07 | $11.19 | $8.77 - $13.51 | +7.86% | Beat | +1.8% | 21 | 6 up, 11 down | Feb 4, 2025 | $3.79B |
| Sep 30, 2024 | $12.46 | $11.70 | $10.14 - $13.56 | +6.50% | Beat | +7.5% | 22 | 4 up, 2 down | Oct 31, 2024 | $3.72B |
| Jun 30, 2024 | $11.56 | $10.62 | $8.90 - $13.18 | +8.85% | Beat | +12.9% | 23 | 6 up, 0 down | Aug 1, 2024 | $3.55B |
| Mar 31, 2024 | $9.55 | $10.10 | $8.56 - $11.62 | -5.45% | Miss | -5.4% | 22 | 5 up, 1 down | May 2, 2024 | $3.15B |
| Dec 31, 2023 | $11.86 | $10.75 | $7.53 - $13.48 | +10.33% | Beat | -5.6% | 21 | 3 up, 4 down | Feb 2, 2024 | $3.43B |
| Sep 30, 2023 | $11.59 | $10.78 | $8.60 - $12.05 | +7.51% | Beat | +4.0% | 21 | 1 up, 1 down | Nov 2, 2023 | $3.36B |
| Jun 30, 2023 | $10.24 | $9.90 | $7.83 - $10.84 | +3.43% | Beat | +4.8% | 20 | 3 up, 0 down | Aug 3, 2023 | $3.16B |
| Mar 31, 2023 | $10.09 | $9.56 | $7.74 - $10.95 | +5.54% | Beat | -12.2% | 20 | 0 up, 2 down | May 4, 2023 | $3.16B |
| Dec 31, 2022 | $12.56 | $10.01 | $5.12 - $12.69 | +25.47% | Beat | -47.0% | 21 | 0 up, 5 down | Feb 3, 2023 | $3.41B |
| Sep 30, 2022 | $11.14 | $9.48 | $2.83 - $11.66 | +17.51% | Beat | -27.5% | 21 | 2 up, 0 down | Nov 3, 2022 | $2.94B |
| Jun 30, 2022 | $9.77 | $8.76 | $7.46 - $13.46 | +11.53% | Beat | -62.1% | 17 | 0 up, 4 down | Aug 3, 2022 | $2.86B |
| Mar 31, 2022 | $11.49 | $9.80 | $8.37 - $11.23 | +17.24% | Beat | +16.2% | 14 | 4 up, 1 down | May 4, 2022 | $2.97B |
| Dec 31, 2021 | $23.72 | $20.30 | $10.35 - $23.20 | +16.85% | Beat | +148.9% | 14 | 6 up, 2 down | Feb 4, 2022 | $4.95B |
| Sep 30, 2021 | $15.37 | $9.94 | $4.55 - $10.83 | +54.63% | Beat | +83.9% | 14 | 1 up, 0 down | Nov 4, 2021 | $3.45B |
| Jun 30, 2021 | $25.80 | $17.71 | $6.63 - $24.55 | +45.68% | Beat | +260.3% | 18 | N/A | Aug 5, 2021 | $5.14B |
| Mar 31, 2021 | $9.89 | $8.68 | $7.11 - $12.63 | +13.94% | Beat | +49.8% | 19 | N/A | May 6, 2021 | $2.53B |
| Dec 31, 2020 | $9.53 | $8.29 | $5.35 - $11.13 | +14.96% | Beat | +27.1% | 21 | N/A | Feb 5, 2021 | $2.42B |
| Sep 30, 2020 | $8.36 | $6.99 | $5.06 - $10.43 | +19.60% | Beat | +25.3% | 17 | N/A | Nov 5, 2020 | $2.29B |
| Jun 30, 2020 | $7.16 | $5.97 | $4.41 - $7.15 | +19.93% | Beat | +18.9% | 20 | N/A | Aug 5, 2020 | $1.95B |
| Mar 31, 2020 | $6.60 | $6.09 | $4.78 - $7.38 | +8.37% | Beat | +48.3% | 19 | N/A | May 5, 2020 | $1.83B |
| Dec 31, 2019 | $7.50 | $7.17 | $5.18 - $8.30 | +4.60% | Beat | +9.6% | 19 | N/A | Feb 6, 2020 | $1.86B |
| Sep 30, 2019 | $6.67 | $6.40 | $5.41 - $7.17 | +4.22% | Beat | +13.6% | 19 | N/A | Nov 5, 2019 | $1.74B |
| Jun 30, 2019 | $6.02 | $5.42 | $4.99 - $5.65 | +11.07% | Beat | +10.5% | 17 | N/A | Aug 6, 2019 | $1.58B |
| Mar 31, 2019 | $4.45 | $5.52 | $4.50 - $6.32 | -19.38% | Miss | -4.7% | 19 | N/A | May 7, 2019 | $1.37B |
| Dec 31, 2018 | $6.84 | $5.60 | $4.60 - $6.57 | +22.14% | Beat | +30.8% | 20 | N/A | Feb 6, 2019 | $362.60M |
| Sep 30, 2018 | $5.87 | $5.06 | $4.44 - $6.04 | +16.01% | Beat | +47.1% | 21 | N/A | Nov 6, 2018 | $1.66B |
| Jun 30, 2018 | $5.45 | $4.68 | $4.14 - $5.35 | +16.45% | Beat | +30.7% | 21 | N/A | Aug 2, 2018 | $1.61B |
| Mar 31, 2018 | $4.67 | $4.34 | $3.58 - $6.59 | +7.60% | Beat | +59.9% | 22 | N/A | May 3, 2018 | $1.51B |
| Dec 31, 2017 | $5.23 | $4.57 | $2.95 - $5.13 | +14.44% | Beat | +72.0% | 24 | N/A | Feb 8, 2018 | $1.58B |
| Sep 30, 2017 | $3.99 | $3.82 | $3.15 - $4.48 | +4.45% | Beat | +27.5% | 23 | N/A | Nov 8, 2017 | $1.50B |
| Jun 30, 2017 | $4.17 | $3.18 | $2.82 - $3.50 | +31.13% | Beat | +47.9% | 21 | N/A | Aug 3, 2017 | $1.47B |
| Mar 31, 2017 | $2.92 | $3.07 | N/A | -4.89% | Miss | +13.6% | N/A | N/A | May 4, 2017 | $1.32B |
| Dec 31, 2016 | $3.04 | $3.05 | N/A | -0.33% | Miss | +7.4% | N/A | N/A | Feb 9, 2017 | $1.23B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $44.38, down 2.8% from the year before. It was $11.56 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $44.38 | -2.8% |
| Dec 31, 2024 | $45.64 | +4.2% |
| Dec 31, 2023 | $43.78 | -2.6% |
| Dec 31, 2022 | $44.96 | -39.9% |
| Dec 31, 2021 | $74.78 | +136.3% |
| Dec 31, 2020 | $31.65 | +28.4% |
| Dec 31, 2019 | $24.64 | +7.9% |
| Dec 31, 2018 | $22.83 | +40.0% |
| Dec 31, 2017 | $16.31 | +41.1% |
| Dec 31, 2016 | $11.56 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,500 words across 16 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,529 | 16 | |
| 2026Q2 | Jun 30, 2026 | 8,481 | 17 | |
| 2026Q1 | Mar 31, 2026 | 8,034 | 19 | |
| 2025Q4 | Dec 31, 2025 | 9,480 | 16 | |
| 2025Q3 | Sep 30, 2025 | 9,164 | 19 | |
| 2025Q2 | Jun 30, 2025 | 8,880 | 19 | |
| 2025Q1 | Mar 31, 2025 | 7,866 | 17 | |
| 2024Q4 | Dec 31, 2024 | 8,703 | 18 |
2026Q3 Earnings Call
Opening remarks
Ryan Crowe Senior Vice President, Investor Relations Thank you, Shannon. Good morning, good afternoon, and good evening to everyone listening around the world. Thank you for your interest in Regeneron, and welcome to our third quarter 2020 earnings conference call. An archive and transcript of this call will be available on the Regeneron Investor Relations website shortly after our call concludes. Joining me on today's call are Dr. Leonard S. Schleifer, cofounder, board cochair, president and chief executive officer; Dr. George D. Yancopoulos, cofounder, board cochair, president, and chief scientific officer; Marion McCourt, executive vice president, commercial; and Christopher R. Fenimore, executive vice president, finance, and chief financial officer. For our call today, Len will briefly review key third quarter performance drivers and highlight a few emerging pipeline programs. George will then detail our recent pipeline progress, followed by Marion, who will review our commercial performance. Finally, Christopher will discuss our financial results and outlook. After our prepared remarks, the remaining time will be available for Q&A. I would like to remind you that remarks made on today's call may include forward-looking statements about Regeneron. Such statements may include, but are not limited to, those related to Regeneron and its products and business, financial forecast and guidance, development programs and related anticipated milestones, collaborations, finances, regulatory matters, payer coverage and reimbursement, changes to drug pricing regulations and requirements, and our drug pricing strategy, intellectual property, pending litigation, other proceedings, and competition. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-Q for the quarter ended September 30, 2026, which was filed with the SEC this morning. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. In addition, please note that GAAP and non-GAAP financial measures will be discussed on today's call. Information regarding our use of non-GAAP financial measures and a reconciliation of those measures to GAAP is available in our quarterly results press release and our corporate presentation, both of which can be found on the Regeneron Investor Relations website. Once our call concludes, the IR team will be available to answer any further questions. With that, let me turn the call over to our president and chief executive, Dr. Leonard S. Schleifer.
Leonard S. Schleifer President and Chief Executive Officer Thank you, Ryan, and welcome to everyone joining our call today.
Frequently Asked Questions About REGN
When is Regeneron Pharmaceuticals's next earnings date?
Regeneron Pharmaceuticals's next earnings report is expected for Jan 28, 2027.
Did REGN beat earnings estimates last quarter?
Yes. Regeneron Pharmaceuticals reported EPS of $18.43 for the quarter ended Sep 30, 2026, above the $13.76 estimate, a 33.94% surprise.
What EPS do analysts expect from REGN next quarter?
The consensus EPS estimate for Regeneron Pharmaceuticals for the quarter ending Dec 31, 2026 is $26.27 from 25 analysts, with estimates from $17.35 to $31.96.
How often does REGN beat earnings estimates?
Regeneron Pharmaceuticals beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +22.95%.
REGN pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts